Your browser doesn't support javascript.
loading
NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023.
Zelenetz, Andrew D; Gordon, Leo I; Abramson, Jeremy S; Advani, Ranjana H; Andreadis, Babis; Bartlett, Nancy L; Budde, L Elizabeth; Caimi, Paolo F; Chang, Julie E; Christian, Beth; DeVos, Sven; Dholaria, Bhagirathbhai; Fayad, Luis E; Habermann, Thomas M; Hamid, Muhammad Saad; Hernandez-Ilizaliturri, Francisco; Hu, Boyu; Kaminski, Mark S; Karimi, Yasmin; Kelsey, Christopher R; King, Rebecca; Krivacic, Susan; LaCasce, Ann S; Lim, Megan; Messmer, Marcus; Narkhede, Mayur; Rabinovitch, Rachel; Ramakrishnan, Praveen; Reid, Erin; Roberts, Kenneth B; Saeed, Hayder; Smith, Stephen D; Svoboda, Jakub; Swinnen, Lode J; Tuscano, Joseph; Vose, Julie M; Dwyer, Mary A; Sundar, Hema.
Affiliation
  • Zelenetz AD; Memorial Sloan Kettering Cancer Center.
  • Gordon LI; Robert H. Lurie Comprehensive Cancer Center of Northwestern University.
  • Abramson JS; Massachusetts General Hospital Cancer Center.
  • Advani RH; Stanford Cancer Institute.
  • Andreadis B; UCSF Helen Diller Family Comprehensive Cancer Center.
  • Bartlett NL; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine.
  • Budde LE; City of Hope National Medical Center.
  • Caimi PF; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute.
  • Chang JE; University of Wisconsin Carbone Cancer Center.
  • Christian B; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute.
  • DeVos S; UCLA Jonsson Comprehensive Cancer Center.
  • Dholaria B; Vanderbilt-Ingram Cancer Center.
  • Fayad LE; The University of Texas MD Anderson Cancer Center.
  • Habermann TM; Mayo Clinic Comprehensive Cancer Center.
  • Hamid MS; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center.
  • Hernandez-Ilizaliturri F; Roswell Park Comprehensive Cancer Center.
  • Hu B; Huntsman Cancer Institute at the University of Utah.
  • Kaminski MS; University of Michigan Rogel Cancer Center.
  • Karimi Y; University of Michigan Rogel Cancer Center.
  • Kelsey CR; Duke Cancer Institute.
  • King R; Mayo Clinic Comprehensive Cancer Center.
  • Krivacic S; Consultant.
  • LaCasce AS; Dana-Farber/Brigham and Women's Cancer Center.
  • Lim M; Memorial Sloan Kettering Cancer Center.
  • Messmer M; Fox Chase Cancer Center.
  • Narkhede M; O'Neal Comprehensive Cancer Center at UAB.
  • Rabinovitch R; University of Colorado Cancer Center.
  • Ramakrishnan P; UT Southwestern Simmons Comprehensive Cancer Center.
  • Reid E; UC San Diego Moores Cancer Center.
  • Roberts KB; Yale Cancer Center/Smilow Cancer Hospital.
  • Saeed H; Moffitt Cancer Center.
  • Smith SD; Fred Hutchinson Cancer Center.
  • Svoboda J; Abramson Cancer Center at the University of Pennsylvania.
  • Swinnen LJ; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
  • Tuscano J; UC Davis Comprehensive Cancer Center.
  • Vose JM; Fred & Pamela Buffett Cancer Center.
  • Dwyer MA; National Comprehensive Cancer Network.
  • Sundar H; National Comprehensive Cancer Network.
J Natl Compr Canc Netw ; 21(11): 1118-1131, 2023 11.
Article in En | MEDLINE | ID: mdl-37935098
ABSTRACT
Novel targeted therapies (small molecule inhibitors, antibody-drug conjugates, and CD19-directed therapies) have changed the treatment landscape of relapsed/refractory B-cell lymphomas. Bruton's tyrosine kinase (BTK) inhibitors continue to evolve in the management of mantle cell lymphoma (MCL), in both the relapsed/refractory and the frontline setting. Anti-CD19 CAR T-cell therapies are now effective and approved treatment options for relapsed/refractory follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), and MCL. Bispecific T-cell engagers represent a novel immunotherapeutic approach for relapsed FL and DLBCL after multiple lines of therapies, including prior CAR T-cell therapy. These NCCN Guideline Insights highlight the significant updates to the NCCN Guidelines for B-Cell Lymphomas for the treatment of FL, DLBCL, and MCL.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Lymphoma, Follicular / Lymphoma, Large B-Cell, Diffuse / Lymphoma, Mantle-Cell Limits: Adult / Humans Language: En Journal: J Natl Compr Canc Netw Year: 2023 Document type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Lymphoma, Follicular / Lymphoma, Large B-Cell, Diffuse / Lymphoma, Mantle-Cell Limits: Adult / Humans Language: En Journal: J Natl Compr Canc Netw Year: 2023 Document type: Article